Human Normal Immunoglobulin and Anti-D Immunoglobulin (CMU Call Off)

Description

National Framework Agreement for the supply of Human Normal Immunoglobulin and Anti-D Immunoglobulin. The framework will commence on 1 July 2021 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Lot 1: 5% Intravenous Immunoglobulin (5% IVIg) - Existing Business Supply of Human Normal Intravenous Immunoglobulin 5 %, across various vial sizes. Lot 2: 10% Intravenous Immunoglobulin (10% IVIg) - Existing Business Supply of Human Normal Intravenous Immunoglobulin 10 %, across various vial sizes. Lot 3: Subcutaneous Immunoglobulin (SCIg) - Existing Business Supply of Human Normal Intravenous Immunoglobulin for subcutaneous use across various vial sizes Lot 4: Facilitated Subcutaneous Immunoglobulin (fSCIg) - Existing Business Supply of Subcutaneous Immunoglobulin with Hyaluronidase (Facilitated Subcutaneous Immunoglobulin) Lot 5: 5% Intravenous Immunoglobulin (5% IVIg) - New Business Supply of Human Normal Intravenous Immunoglobulin 5 %, across various vial sizes for new patients. Lot 6: 10% Intravenous Immunoglobulin (10% IVIg) - New Business Supply of Human Normal Intravenous Immunoglobulin 10 %, across various vial sizes for new patients. Lot 7: Subcutaneous Immunoglobulin (SCIg) - New Business Supply of Human Normal Intravenous Immunoglobulin for subcutaneous use across various vial sizes for new patients. Lot 8: Facilitated Subcutaneous Immunoglobulin (fSCIg) - New Business Supply of Subcutaneous Immunoglobulin with Hyaluronidase (Facilitated Subcutaneous Immunoglobulin) for new patients. Lot 9: Anti-D Immunoglobulin (Anti-D) Supply of Anti-D Immunoglobulin